Compare Illumina, Inc. (ILMN) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ArcelorMittal SA — how do they compare? Illumina, Inc. trades at $267.69 (market cap $39.95B), while ArcelorMittal SA trades at $64.05 (market cap $45.70B). The key difference: Illumina, Inc. and ArcelorMittal SA are close in size by market cap, and ArcelorMittal SA pays a 0.98% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ArcelorMittal SA for 36 Days on average.
| ILMN | MT | |
|---|---|---|
Market Cap | $39.95B | $45.70B |
Volume | 3,169,503 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $293.69 | $78.74 |
52-Week Low | $91.00 | $36.91 |
Typical Hold Time | 83 Days | 36 Days |
Enterprise Value | $41.31B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
ArcelorMittal (MT) trades at $62.32, down 4.4% on the day, amid a bearish technical setup and recent operational disruptions in Ukraine. The stock shows mixed fundamentals with a low P/S of 0.75 and P/B of 0.84, but profitability metrics like net margin (2.88%) and ROE (3.32%) remain modest. Recent Q2 2026 earnings missed estimates, though Q1 and Q4 2025 beat expectations. Analyst consensus is bullish with a $74.33 price target, but technical indicators signal caution.
The outlook is clouded by near-term headwinds including the Ukraine plant impairment and volatile steel demand, yet long-term value is supported by low valuation multiples and strategic regionalization efforts. Risks include geopolitical exposure and cyclical industry pressures, but institutional sentiment remains positive with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
